A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR

Journal of Clinical Psychopharmacology

Volumn 28, Issue 3, 2008, Pages 329-333

  Kennedy, Sidney H ^a,b   Rizvi, Sakina ^a,b   Fulton, Kari ^b   Rasmussen, Jill ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Psi Napse   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; VENLAFAXINE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; HYPNOTIC SEDATIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; LIBIDO; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; NAUSEA; ORGASM; ORGASM DISORDER; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL AROUSAL DISORDER; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; UPPER RESPIRATORY TRACT INFECTION; AROUSAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; PERSONALITY TEST; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AROUSAL; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LIBIDO; MALE; MIDDLE AGED; ORGASM; PERSONALITY INVENTORY; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 51449112441     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318172b48c     Document Type: Article

References (27)

1. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93-100.
2. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
3. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;4:1-13.
4. Thase ME, Entsuah R, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
5. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000;61:276-281.
6. Montejo AL, Llorca G, Izquierdo JA, et al, for the SpanishWorking Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;63:10-21.
7. Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006;26:482-488.
8. Clayton AH. Sexual function and dysfunction in women. Psychiatr Clin North Am. 2003;26:673-678.
9. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs. 1999;57:607-631.
10. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22:444-447.
11. Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord. 2002;69:119-140.
12. Casper RC, Redmond DE Jr, Katz MM, et al. Somatic symptoms in primary affective disorders: presence and relationship to the classification of depression. Arch Gen Psychiatry. 1985;42:1098-1104.
13. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63:357-366.
14. Kennedy SH, Dickens SE, Eisfeld BS, et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999;56: 201-208.
15. McIntyre RS, Kennedy SH, Bagby RM, et al. Assessing full remission. J Psychiatry Neurosci. 2002;27:235-239.
16. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36:1577-1579.
17. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry. 2006;51:234-242.
18. Montgomery SA, A° sberg M. A new depression scale designed to be sensitive to change. Brit J Psych. 1979;134:382-389.
19. Drago F, Busa L. Acute low doses of melatonin restore full sexual activity in impotent male rats. Brain Res. 2000;878:98-104.
20. Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behaviour. Physiol Behav. 2004;83:291-307.
21. Klint T, Larsson K. Clozapine acts as a 5HT2 antagonist by attenuating DOI-induced inhibition of male rat sexual behaviour. Psychopharmacol. 1995;119:291-294.
22. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry. 1994;164:838-839.
23. Keller-Ashton A, Hamer R, Rosen RC. Serotonin reuptake inhibitorinduced sexual dysfunction and its treatment: a large scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther. 1997;23:165-175.
24. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressantinduced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord. 2005;88:241-254.
25. Saiz-Ruiz J, Montes JM, Ibanez A, et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol. 2005;20:435-440.
26. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731-745.
27. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine compared to paroxetine in healthy male volunteers using the PRSexDQ Scale. Eur J Neuropsychopharmacol. 2007;17:S349.